Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: Correlation with c-Myc suppression

Cancer Research

Volumn 58, Issue 16, 1998, Pages 3684-3693

  Medh, Rheem D ^a   Saeed, Mohammad F ^a   Johnson, Betty H ^a   Thompson, E Brad ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEXAMETHASONE; DNA; FORSKOLIN; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; ONCOGENE C MYC; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

APOPTOSIS; CELL SURVIVAL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEXAMETHASONE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FORSKOLIN; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MIFEPRISTONE; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0032529237     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Munck, A., and Crabtree, G. R. Glucocorticoid-induced lymphocyte death. In: I. D. Bowen and R. A. Lockshin (eds.), Cell Death in Biology and Pathology, pp. 329-359. New York: Chapman and Hall, 1981.
2. Thompson, E. B. Apoptosis and steroid hormones. Mol. Endocrinol. 8: 665-673, 1994.
3. Norman, M. R., and Thompson, E. B. Characterization of a glucocorticoid-sensitive human lymphoid cell line. Cancer Res., 37: 3785-3791, 1977.
4. Miesfeld, R., Okret, S., Wikström, A-C., Wrange, Ö., Gustafsson, J-Å., and Yamamoto, K. R. Characterization of a steroid receptor gene and mRNA in wild type and mutant cells. Nature (Lond.), 312: 779-781, 1984.
5. Ashraf, J., and Thompson, E. B. Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes. Mol. Endocrinol. 7: 631-642, 1993.
6. Sibley, C. H., and Tomkins, G. M. Isolation of lymphoma cell variants resistant to killing by glucocorticoids. Cell, 2: 213-220, 1974.
7. Pfahl, M., Kelleher, R. J., Jr., and Bourgeois, S. General features of steroid resistance in lymphoid cell lines. Mol. Cell. Endocrinol., 10: 193-207, 1978.
8. Harmon, J. M., and Thompson, E. B. Isolation and characterization of dexamethasone-resistant mutants from human lymphoid cell line CEM-C7. Mol. Cell. Biol., 1: 512-521, 1981.
9. Bourgeois, S., and Newby, R. F. Correlation between glucocorticoid receptor and cytolytic response of murine lymphoid cell line. Cancer Res., 39: 4749-4751, 1979.
10. Philips, H. J. In: P. F. Kruse and M. K. Patterson (eds.), Dye exclusion test for cell viability. Tissue Culture: Methods and Applications, pp. 406-408. New York: Academic Press, 1973.
11. Kato, G. J., Quddus, F. F., Shuster, J. J., Boyett, J., Pullen, J. D., Borowitz, M. J., Whitehead, V. M., Crist, W. M., and Leventhal, B. G. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood, 82: 2304-2309, 1993.
12. Eisen, L. P., Elsasser, M. S., and Harmon, J. M. Positive regulation of the glucocorticoid receptor in human T-cells sensitive to the cytolytic effects of glucocorticoids. J. Biol. Chem., 263: 12044-12048, 1988.
13. Denton, R. R., Eisen, L. P., Elsasser, M. S., and Harmon, J. M. Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines. Endocrinology, 133: 248-256, 1993.
14. Kaspers, G. J., Pieters, R., Klumper, E., DeWaal, F. C., and Veerman, A. J. Glucocorticoid resistance in childhood leukemia. Leukemia Lymphoma, 13: 187-201, 1994.
15. Yamamoto, K. R., Gehring, U. A., Stampfer, M., and Sibley, C. H. Genetic approaches to steroid hormone action. Rec. Prog. Horm. Res., 32: 3-32, 1976.
16. Bourgeois, S., Newby, R. F., and Huet, M. Glucocorticoid resistance in murine lymphoma and thymoma lines. Cancer Res., 38: 4279-4284, 1978.
17. Thompson, E. B., and Harmon, J. M. In: G. P. Choursos, D. L. Louriaux, and M. B. Lipsett (eds.), Steroid Hormone Resistance, pp. 111-127. New York: Plenum Publishing Corp., 1986.
18. Soufi, M., Schneider, A., Beato, M., and Westphal, H. M. The DNA and steroid binding domains of the glucocorticoid receptor are not altered in mononuclear cells of treated CLL patients. Exp. Clin. Endocrinol. Diabetes, 103: 175-183, 1995.
19. Thompson, E. A. Glucocorticoid insensitivity of P1798 lymphoma cells is associated with production of a factor that attenuates the lytic response. Cancer Res., 51: 5551-5556, 1991.
20. Bourgeois, S., Gruol, D. J., Newby, R. F., and Rajah, F. M. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol. Endocrinol., 7: 840-851, 1993.
21. Zhou, F., and Thompson, E. B. Role of c-jun induction in the glucocorticoid-evoked apoptotic pathway in human leukemic lymphoblasts. Mol. Endocrinol., 10: 306-316, 1996.
22. Thulasi, R., Harbour, D. V., and Thompson, E. B. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J. Biol. Chem., 268: 18306-18312, 1993.
23. Gordeladze, J. O., Johansen, P. W., Paulssen, R. H., Paulssen, E. J., and Gautvik. K. M. G-proteins: implications for pathophysiology and disease. Eur. J. Endocrinol., 131: 557-574, 1994.
24. Schule, R., and Evans, R. M. Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet., 7: 377-381, 1991.
25. Nordeen, S. K., Bona, B. J., and Moyer, M. L. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol., 7: 731-742, 1993.
26. Dong, Y., Aronsson, M., Gustafsson, J. A., and Okret, S. The mechanism of cAMP-induced glucocorticoid receptor expression. Correlation to cellular glucocorticoid response. J. Biol. Chem., 264: 13679-13683, 1989.
27. Jondal, M., Xue, Y., McConkey D. J., and Okret, S. Thymocyte apoptosis by glucocorticoids and cAMP. In: G. Kroemer and A. C. Martinez (eds.), Current Topics in Microbiology and Immunology: Apoptosis in Immunology, Vol. 200, pp. 67-79. Berlin: Springer-Verlag, 1995.
28. Dowd, D. R., and Miesfeld, R. L. Evidence that glucocorticoid-and cyclic AMP-induced apoptotic pathways in lymphocytes share distal events. Mol. Cell. Biol., 12: 3600-3608.
29. Gruol, D. J., Rajah, F. M., and Bourgeois, S. Cyclic AMP-dependent protein kinase modulation of the glucocorticoid-induced cytolytic response in murine T-lymphoma cells. Mol. Endocrinol. 3: 2119-2127, 1989.
30. McConkey, D. J., Orrenius, S., Okret, S., and Jondal, M. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. FASEB J., 7: 580-585, 1993.
31. McConkey, D. J., Orrenius, S., and Jondal, M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J. Immunol., 145: 1227-1230, 1990.
32. Montminy, M. Transcriptional regulation by cyclic AMP. Annu. Rev. Biochem., 66: 807-822, 1997.
33. Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (Lond.), 365: 855-859, 1993.
34. Shibata, H., Spencer, T. E., Onate, S. A., Jenster, G., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Rec. Prog. Hormone Res., 52: 141-165, 1997.
35. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85: 403-414, 1996.
36. Rhee, K., Bresnahan, W., Hirai, A., Hirai, M., and Thompson, E. A. c-myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res., 55: 4188-4195, 1995.
37. Thompson, E. B., Thulasi, R., Saeed, M. F., and Johnson, B. H. Glucocorticoid antagonist RU 486 reverses agonist-induced apoptosis and c-myc repression in human leukemic CEM-C7 cells. Ann. N. Y. Acad. Sci., 761: 261-277, 1995.
38. Eastman-Reks, S. B., and Vedeckis, W. V. Glucocorticoid inhibition of c-myc, c-myb, c-Ki-ras expression in a mouse lymphoma cell line. Cancer Res., 46: 2457-2462, 1986.
39. Helmberg, A., Auphan, N., Caelles, C., and Karin, M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J., 14: 452-460, 1995.
40. Forsthoefel, A. M., and Thompson, E. A. Glucocorticoid regulation of transcription of the c-myc cellular protooncogene in P1798 cells. Mol. Endocrinol., 1: 899-907, 1987.
41. Zawydiwski, R., Harmon, J. M., and Thompson, E. B. Glucocorticoid-resistant human acute lymphoblastic leukemic cell line with functional receptor. Cancer Res., 43: 3865-3873, 1983.
42. Denton, R. R., Eisen, L. P., Elsasser, M. S., and Harmon, J. M. Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines. Endocrinology, 133: 248-256, 1993.
43. Srinivasan, G., Patel, N. T., and Thompson, E. B. Heat shock protein is tightly associated with the recombinant human glucocorticoid receptor: glucocorticoid response element complex. Mol. Endocrinol., 8: 189-196, 1994.
44. Evan, G. I., Lewis, G. K., and Bishop, J. M. Isolation of monoclonal antibodies specific for products of avian oncogene myb. Mol. Cell. Biol., 4: 2843-2850, 1984.
45. Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A., and McCarthy, R. E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer (Phila.), 18: 522-529, 1965.
46. Smith, J. S., Kawa, S. Cloyd, M. W., and Thompson, E. B. Interactions between human immunodeficiency virus infection and hormonal pathways: enhancement of calcium-induced but reduction of glucocorticoid-induced cell death. Endocrinology, 133: 1085-1091, 1993.
47. Johnson, B. H., Ayala-Torres, S., Chan, L-N. L., El-Naghy, M., and Thompson, E. B. Glucocorticoid/oxysterol-induced DNA lysis in human leukemic cells. J. Steroid Biochem. Mol. Biol., 61: 35-45, 1997.
48. Laemmli, U. K. Clevage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 277: 680-685, 1970.
49. Nordeen, S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques, 6: 454-458, 1988.
50. Bourgeois, S., Pfahl, M., and Baulieu, E. E. DNA binding properties of glucocorticoid receptor bound to the steroid antagonist RU-486. EMBO J., 3: 751-755, 1984.
51. Horwitz, K. B. The molecular biology of RU486. Is there a role for anti progestins in the treatment of breast cancer? Endocrinol. Rev., 13: 146-163, 1992.
52. Thompson, E. B., Thulasi, R., Saeed, M. F., and Johnson, B. H. Glucocorticoid antagonist RU486 reverses agonist-induced apoptosis and c-myc repression in the human leukemic CEM-C7 cells. Ann. N. Y. Acad. Sci., 761: 261-273, 1995.
53. Vanderbilt, J. N., Miesfeld, R., Maler, B. A., and Yamamoto, K. R. Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol. Endocrinol., 1: 68-74, 1987.
54. Geley, S., Hartmann, B. L., Hala, M., Strasser-Wozak, E. M. C., and Kofler, R. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res., 56: 5033-5038, 1996.
55. Cidlowski, J. A., and Cidlowski, N. B. Regulation of glucocorticoid receptor by glucocorticoids in cultured HeLa S3 cells. Endocrinology, 109: 1975-1982, 1981.
56. Imai, E., Miner, J. N., Mitchell, J. A., Yamamoto, K. R., and Granner, D. K. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J. Biol. Chem., 268: 5353-5356, 1993.
57. Verbeeck, M. A., Sutanto, W., and Burbach, J. P. Regulation of vasopressin messenger RNA levels in the small cell lung carcinoma cell line GLC-8: interactions between glucocorticoids and second messengers. Mol. Endocrinol., 5: 795-801, 1991.
58. Keifer, J., Okret, S., Jondal, M., and McConkey, D. J. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J. Immunol., 155: 4525-4528, 1995.
59. Okret, A., Dong, Y., Tanaka, H., Cairns, B., and Gustafsson, J. The mechanism for glucocorticoid-resistance in a rat hepatoma cell variant that contains functional glucocorticoid receptor. J. Steroid Biochem. Mol. Biol., 40: 353-361, 1991.
60. Dong, Y., Caims, W., Okret, S., and Gustafsson, J. A. A glucocorticoid-resistant variant contains functional glucocorticoid receptor. J. Biol. Chem., 265: 7526-7531, 1990.
61. 2+-, cAMP-, and glucocorticoid-induced gene expression in lymphocytes. Mol. Cell. Endocrinol., 128: 29-37, 1997.
62. Albert, D. A. The effect of cyclic-AMP on the regulation of c-myc expression in T lymphoma cells. J. Clin. Invest., 95: 1490-1496, 1995.
63. Andersson, K. B., Tasken, K., and Blomhoff, H. K. Cyclic AMP downregulates c-myc expression by inhibition of transcript initiation in human B-precursor Reh cells. FEBS Lett., 337: 71-76, 1994.
64. Andersson, K. B., Deggerdal, A., Skjonsberg, C., Smeland, E. B., and Blomhoff, H. K. Constitutive expression of c-myc does not relieve cAMP-mediated growth arrest in human lymphoid Reh cells. J. Cell. Physiol., 157: 61-69, 1993.